Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ER+/ HER2-ve Breast Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, G1 Therapeutics, Genetech, Roche, Sanofi, AstraZeneca and Many Others

06/16/2021 | 04:08am EDT

Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. The backbone of their systemic therapy consists of hormonal therapies that block the function of ER through various mechanisms. These include blockade of the receptor itself in breast cancer cells, blockade of the production of its major ligand, estradiol, or degradation of the receptor. However, a subset of ER+/HER2- breast cancers, mostly corresponding to the genomic luminal B genotype, are resistant to hormonal manipulations from the outset of therapies.

DelveInsight's, "ER+/ HER2-ve Breast Cancer Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ER+/ HER2 -ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request for free Sample Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

ER+/ HER2-ve Breast Cancer Key Players:*Eisai *G1 Therapeutics *Genetech/La Roche *Sanofi *AstraZeneca *And Many Others

DelveInsight's ER+/ HER2-ve Breast Cancer report covers around 5+ products under different phases of clinical development like:*Late-stage products (Phase III) *Mid-stage products (Phase II and Phase I/II) *Early-stage products (Phase I/II and Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates

Request for free Sample Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

ER+/ HER2-ve Breast Cancer Therapies:*H3B-6545 *G1T48 *GDC-9545 *SAR439859 *AZD9833 *And Many Others

Current ER+/ HER2-ve Breast Cancer Treatment Scenario and ER+/ HER2-ve Breast Cancer Emerging Therapies:*How many companies are developing ER+/ HER2 -ve Breast Cancer drugs? *How many ER+/ HER2 -ve Breast Cancer drugs are developed by each company? *How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ER+/ HER2 -ve Breast Cancer? *What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ER+/ HER2 -ve Breast Cancer therapeutics? *What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? *What are the clinical studies going on for ER+/ HER2 -ve Breast Cancer and their status? *What are the key designations that have been granted to the emerging drugs?

Request for free Sample Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

Table of Contents:


Executive Summary

ER+/ HER2 -ve Breast Cancer: Overview

Pipeline Therapeutics

* Comparative Analysis

Therapeutic Assessment

ER+/ HER2 -ve Breast Cancer - DelveInsight's Analytical Perspective

In-depth Commercial Assessment

ER+/ HER2 -ve Breast Cancer Collaboration Deals

Late Stage Products (Phase III)

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

* Comparative Analysis

Rintodestrant (G1T48): G1 Therapeutics

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Drug profiles in the detailed report.....

Inactive Products

* Comparative Analysis

ER+/ HER2 -ve Breast Cancer Key Companies

ER+/ HER2 -ve Breast Cancer Key Products

ER+/ HER2 -ve Breast Cancer- Unmet Needs

ER+/ HER2 -ve Breast Cancer- Market Drivers and Barriers

ER+/ HER2 -ve Breast Cancer- Future Perspectives and Conclusion

ER+/ HER2 -ve Breast Cancer Analyst Views

ER+/ HER2 -ve Breast Cancer Key Companies


Request for Detailed TOC: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

Address:304 S. Jones Blvd #2432

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight

Source: www.abnewswire.com


(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.08% 8288 Delayed Quote.13.22%
EISAI CO., LTD. 3.45% 9456 End-of-day quote.28.27%
G1 THERAPEUTICS, INC. -0.23% 17.63 Delayed Quote.-2.00%
SANOFI -0.98% 86.76 Real-time Quote.11.28%
All news about EISAI CO., LTD.
07/26EISAI : Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations..
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
07/22EISAI : FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combinat..
07/21Eisai to present latest data on pipeline assets in the area of alzheimer's di..
07/21BIOGEN : Alzheimer's drug slow to take off as U.S. Medicare wrestles with covera..
07/20EISAI : to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Dis..
07/19EISAI : Status of aduhelm in the united states
07/18EISAI : Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
07/16Nikkei dips below 28,000 as tech stocks track Nasdaq slide
07/15Nikkei breaks below 28,000 as tech stocks track Nasdaq slide
More news
Sales 2022 700 B 6 352 M 6 352 M
Net income 2022 59 105 M 537 M 537 M
Net cash 2022 147 B 1 334 M 1 334 M
P/E ratio 2022 45,8x
Yield 2022 1,71%
Capitalization 2 711 B 24 576 M 24 608 M
EV / Sales 2022 3,66x
EV / Sales 2023 3,47x
Nbr of Employees 11 237
Free-Float 87,5%
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Last Close Price 9 456,00 JPY
Average target price 12 439,23 JPY
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.28.27%24 576
JOHNSON & JOHNSON9.21%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.58%218 198
NOVARTIS AG1.10%207 246